RSV vaccine (Arexvy) — demystified

Does this affect me?

If you're 75 or over (general population) or 60 or over (First Nations Australian), yes — the vaccine is free under the National Immunisation Program. If you're 50-74 and not First Nations, you're not eligible for free yet, but you can pay privately (~$300+ a dose) if you and your GP decide it's worth it. If you're caring for an older relative in either cohort, the vaccine is free for them at any GP or participating pharmacy.

Quick test:

75 or older? Eligible — free at GP or pharmacy. Bring your Medicare card.
First Nations Australian aged 60-74? Eligible — same access, free.
60-74 and not First Nations? Not NIP-eligible. Talk to your GP about risk vs benefit and the ~$300 private cost.
Pregnant or have a newborn? Different vaccine pathway — infants get nirsevimab (a monoclonal antibody), separate program.
Already had your one shot? Currently a single dose. Booster guidance may shift; ask your GP at your next check-in.

TL;DR

The 2026-27 Budget puts up $449.3 million over five years (and $60.9 million a year ongoing) to list the Arexvy® RSV vaccine on the National Immunisation Program (NIP) for adults 75+ (general population) and 60+ (First Nations Australians). The vaccine is free at the needle for eligible cohorts only. It's not free for everyone yet.

Anyone telling you "the RSV vaccine isn't approved in Australia" is wrong. It's approved, NIP-listed and rolling out — just not to every age group.

Jargon decoder:

RSV = Respiratory Syncytial Virus. A common winter respiratory bug. Usually mild, but in older adults and small babies it can cause serious lower-respiratory illness and hospitalisation.

NIP = National Immunisation Program. The federal scheme that funds free vaccines for eligible cohorts. NIP-listed = $0 at the needle for the eligible group.

Arexvy = GlaxoSmithKline's RSV vaccine for adults. The product being funded under NIP for this measure.

Nirsevimab = a monoclonal antibody for infants (not the same product, not the same mechanism). Separate program.

PBAC = Pharmaceutical Benefits Advisory Committee. The independent body that recommends which drugs and vaccines get publicly funded. They signed off on Arexvy for these cohorts.

What's NOT in this budget

Universal free RSV vaccine for all adults.
RSV vaccine for kids (separate paediatric pathway — different product).
RSV monoclonal antibody (nirsevimab) for infants — that's a separate measure with its own funding line.
NIP listing for 50-74-year-olds without specific risk factors.
Mandatory RSV vaccination in workplaces or aged care.

What IS in this budget

The headline numbers

Item	Figure
Total 5-year commitment	$449.3 million
Ongoing annual funding	$60.9 million / year
Product	Arexvy® (GlaxoSmithKline RSV vaccine)
Eligibility — general population	75+ years
Eligibility — First Nations Australians	60+ years
Delivery channel	GPs, pharmacies, community immunisers — under NIP
Cost to eligible patient	$0 (free under NIP)

Why now

RSV is a big cause of hospitalisation in older adults — disease burden sits in the same range as the flu.
Arexvy cut severe RSV disease significantly in clinical trials.
The Pharmaceutical Benefits Advisory Committee (PBAC) recommended NIP listing for these age cohorts.

Why the lower age cut-off for First Nations Australians

First Nations Australians cop earlier onset of age-related conditions.
RSV hospitalisation kicks in younger in First Nations populations.
Lines up with NIP precedent (pneumococcal vaccines, shingles vaccine) of lower age thresholds for First Nations.

Key dates

Event	Date
NIP listing effective	From 2025-26 (already rolling)
Full ongoing funding	$60.9M/yr from 2030-31
Annual delivery window	All year — but most useful pre-winter (March-May)

Worked example — Glenda, 77, no major medical history

Eligible: 75+ general population.
Books in with a GP or pharmacy.
Vaccine cost: $0. The consult might be bulk-billed or have a small gap depending on the provider.
Protection: much lower risk of severe RSV-related hospitalisation through the next winter.

Worked example — Tony, 62, First Nations Australian

Eligible: 60+ First Nations cohort.
Same access pathway — free under NIP.
Same protection profile.

Worked example — Sarah, 70, no risk factors

Not eligible for the NIP-funded shot yet (below the 75 cut-off).
Can pay privately (~$300+ out of pocket through a pharmacy or GP).
Worth a chat with her GP about risk vs benefit for her specifically.

Myths vs reality

Myth 1: "RSV vaccine isn't approved in Australia" — FALSE

It's TGA-approved and now NIP-listed for eligible age cohorts.

Myth 2: "It's free for all adults" — FALSE

Free only for 75+ general or 60+ First Nations. Everyone else pays privately or isn't eligible.

Myth 3: "RSV is just a cold" — MISLEADING

In older adults RSV can cause serious lower-respiratory illness, hospitalisation and death. Disease burden sits in the same range as the flu for this age group.

Myth 4: "If I'm 60 and not First Nations I can still get it free" — FALSE

NIP eligibility for the general population starts at 75. The 60+ door is specific to First Nations Australians.

Myth 5: "$449 million is overkill" — DEPENDS

Modest against the hospitalisation costs it avoids. An RSV hospital admission in older adults runs into thousands of dollars; vaccination at ~$200-300 a dose knocks out a decent share.

Myth 6: "It's the same RSV product as the one for babies" — FALSE

Arexvy is an adult vaccine. Infants get nirsevimab (a monoclonal antibody) — different product, different mechanism, separate program.

Myth 7: "You need a script from your GP" — DEPENDS

Pharmacist-administered routes are expanding. Some states let eligible adults walk straight into a pharmacy. Check with your provider.

Myth 8: "It's a yearly shot like the flu jab" — FALSE

RSV vaccination is currently a single dose; how long protection lasts is still being studied. Booster guidance may shift in coming years.

But what if...

...I'm 76 but didn't get a letter or notification? You don't need a letter. Book in with your GP or check whether your local pharmacy administers Arexvy in your state. Bring your Medicare card. NIP eligibility is automatic for the cohort — there's no separate sign-up.

...I'm 60 and not First Nations, but I have lung disease or am immunocompromised? You're not NIP-eligible based on age alone, but your GP can advise on whether private vaccination at ~$300/dose makes sense for your specific risk profile. The TGA approval covers a broader age range than NIP funding; the funding line just sets who gets it free.

...I'm 72 and First Nations — am I in the eligible cohort? Yes. First Nations eligibility starts at 60, with no upper cap. The lower threshold reflects earlier-onset risk in First Nations populations; the same NIP rules then carry through into the 75+ general cohort.

...I had RSV last year. Do I still need the vaccine? Natural RSV infection doesn't give durable immunity for older adults — you can get it again, and protection from past infection isn't reliable. Talk to your GP about timing, but yes, the vaccine is still recommended for the eligible cohort even if you've had RSV before.

...does the vaccine consult cost anything? The vaccine itself is $0 under NIP. Some GPs bulk-bill the consult on top; others charge a small gap. Many pharmacies that administer NIP vaccines charge $0 for the consult too, but it varies — ring ahead to confirm.

...what about the babies — what's the program for them? Infants get a separate product (nirsevimab — a monoclonal antibody, not a vaccine in the traditional sense). It has its own funding line and rollout. Different mechanism, different age group, different program.

...can I get RSV vaccinated at the same time as my flu shot? Generally yes — co-administration with flu (and often pneumococcal) is standard practice. Your GP or pharmacist will confirm based on your history.

Where genuine debate lives

Whether the NIP age threshold should drop to 65 or 70 as more data lands.
Whether pharmacists should be the default delivery channel to push uptake.
Whether the RSV monoclonal antibody program for infants needs its own, bigger funding line.
Whether messaging needs to land harder in regional and First Nations communities to lift coverage.

A useful filter

Adult or paediatric? Arexvy = adult. Nirsevimab = infant.
75+ general or 60+ First Nations? Two separate eligibility doors.
NIP-funded or private? Free if eligible; about $300+ if you self-fund.
One shot or annual? Currently a single dose; guidance under review.

Sources

Budget Paper 1 — page 16
Budget Paper 2 — page 98
Theme 05 — Care and Opportunity
BP2 Measures Index
PBAC recommendation register, GlaxoSmithKline Arexvy® product information

The $449M RSV vaccine — who qualifies, who pays